NICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drugPreviously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer, will have an immunotherapy-based treatment option Share XNICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drughttps://pharmaphorum.com/news/nice-okays-roche-liver-cancer-immunotherapy-sanofis-rare-disease-drug/
After a nay from NICE, Scotland says aye to J&J’s SpravatoNHS patients with treatment-resistant depression in Scotland will be able to access Johnson & Johnson’s Spravato, a drug Share XAfter a nay from NICE, Scotland says aye to J&J’s Spravatohttps://pharmaphorum.com/news/after-a-nay-from-nice-scotland-says-aye-to-jjs-spravato/
Sanofi’s rare disease drug Cablivi approved in the EUThe European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired Share XSanofi’s rare disease drug Cablivi approved in the EUhttps://pharmaphorum.com/news/sanofi-cablivi-approved-europe/
